diclofenac has been researched along with valdecoxib in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (74.07) | 29.6817 |
| 2010's | 7 (25.93) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Casini, A; Heine, A; Klebe, G; Kuhn, D; Scozzafava, A; Supuran, CT; Weber, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Kent, JD; Leese, PT; Recker, DP; Talwalker, S | 1 |
| Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW | 1 |
| Frölich, JC; Stichtenoth, DO | 1 |
| Pavelka, K; Recker, DP; Verburg, KM | 1 |
| Niculescu, L; Peña, B; von Scheele, B; Wong, J | 1 |
| Burian, M; Geisslinger, G | 1 |
| Bevan, S; Courade, JP; Dawson, J; Fox, A; Glatt, M; Gonzalez, I; Medhurst, S; Urban, L | 1 |
| Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y | 1 |
| Cabrera, J; Calderón, E; Chaves, J; Fernández, S; Martínez, J; Torres, LM | 1 |
| Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A | 1 |
| Hochberg, MC | 1 |
| Meechan, J | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Deray, G; Héloire, F; Valat, JP | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Chakradhar, LV; Naik, SR | 1 |
| Abdalah, MM; Amr, AG; Fakhr, IM; Sabry, NM | 1 |
| Chaignat, V; Danuser, H; Mevissen, M; Stoffel, MH; Studer, UE; Z'brun, S | 1 |
| Elliott, WJ | 1 |
| Fuskevåg, OM; Reikerås, O; Shegarfi, H; Utvåg, SE | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Bartzatt, R | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
9 review(s) available for diclofenac and valdecoxib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The second generation of COX-2 inhibitors: what advantages do the newest offer?
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2003 |
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
7 trial(s) available for diclofenac and valdecoxib
| Article | Year |
|---|---|
Valdecoxib does not impair platelet function.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Bleeding Time; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Naproxen; Platelet Aggregation; Statistics, Nonparametric; Sulfonamides; Thromboxane B2 | 2002 |
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Diclofenac; Double-Blind Method; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacter pylori; Humans; Ibuprofen; Isoenzymes; Isoxazoles; Male; Membrane Proteins; Middle Aged; Osteoarthritis; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Stomach Ulcer; Sulfonamides; Treatment Outcome | 2002 |
Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Humans; Isoenzymes; Isoxazoles; Male; Membrane Proteins; Middle Aged; Pain Measurement; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Sulfonamides; Treatment Outcome | 2003 |
Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cohort Studies; Cost Savings; Cost-Benefit Analysis; Diclofenac; Drug Costs; Female; Health Resources; Hospitalization; Humans; Isoxazoles; Male; Middle Aged; Peptic Ulcer; Sulfonamides | 2003 |
[The specific cox-2 inhibitor valdecoxib provides effective analgesia after inguinal hernia surgery].
Topics: Analgesia; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Female; Hernia, Inguinal; Humans; Isoxazoles; Male; Membrane Proteins; Middle Aged; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Sulfonamides | 2004 |
Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofenac; Double-Blind Method; Dyspepsia; Female; Humans; Ibuprofen; Isoxazoles; Male; Middle Aged; Naproxen; Osteoarthritis; Pain Measurement; Patient Satisfaction; Placebos; Quality of Life; Sulfonamides; Treatment Outcome; Upper Gastrointestinal Tract | 2005 |
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction | 2006 |
11 other study(ies) available for diclofenac and valdecoxib
| Article | Year |
|---|---|
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
Topics: Animals; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Intraocular Pressure; Isoenzymes; Isoxazoles; Kinetics; Lactones; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Structure-Activity Relationship; Sulfonamides; Sulfones | 2004 |
[Pain therapy in rheumatism. After 65 years of age coxibs are the best choice].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Cyclooxygenase Inhibitors; Diclofenac; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Naproxen; Prognosis; Rheumatic Diseases; Sulfonamides | 2003 |
Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Bone Density; Bone Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Freund's Adjuvant; Hyperalgesia; Inflammation; Isoenzymes; Isoxazoles; Organic Chemicals; Pain; Pain Measurement; Prostaglandin-Endoperoxide Synthases; Radiology; Rats; Rats, Sprague-Dawley; Sulfonamides; Time Factors; Tumor Cells, Cultured | 2004 |
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles | 2004 |
Polyamines in inflammation and their modulation by conventional anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell Proliferation; Cyclooxygenase Inhibitors; Dexamethasone; Diclofenac; Drug Interactions; Inflammation; Isoxazoles; Polyamines; Rats; Rats, Wistar; Steroids; Sulfonamides | 2007 |
Anti-inflammatory and analgesic activities of newly synthesized chiral peptide derivatives using (3-benzoyl- 4,5-dioxo-2-phenyl-pyrrolidin-1-yl)acetic acid ethyl ester as starting material.
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Diclofenac; Dose-Response Relationship, Drug; Female; Isoxazoles; Lethal Dose 50; Male; Mice; Pyrrolidines; Rats; Structure-Activity Relationship; Sulfonamides; Toxicity Tests, Acute | 2008 |
Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo.
Topics: Aged; Animals; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Data Interpretation, Statistical; Diclofenac; Dose-Response Relationship, Drug; Electric Stimulation; Female; Humans; Immunohistochemistry; In Vitro Techniques; Isoxazoles; Kidney; Kinetics; Male; Muscle Contraction; Muscle, Smooth; Sulfonamides; Swine; Ureter; Ureteral Obstruction | 2008 |
Short-term treatment with COX-2 inhibitors does not impair fracture healing.
Topics: Animals; Bone Density; Cyclooxygenase 2 Inhibitors; Diclofenac; Fracture Healing; Isoxazoles; Male; Rats; Rats, Wistar; Sulfonamides | 2010 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Design; Humans; Isoxazoles; Models, Molecular; Neoplasms; Pain; Sulfonamides | 2014 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |